Use of brodalumab for the treatment of chronic plaque psoriasis : a one-year real-life study in the Lazio region, Italy
Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 21(2021), 9 vom: 24. Sept., Seite 1299-1310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galluzzo, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6ZA31Y954Z |
|---|
| Anmerkungen: |
Date Completed 31.01.2022 Date Revised 31.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2021.1941862 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326624686 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326624686 | ||
| 003 | DE-627 | ||
| 005 | 20231225195009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2021.1941862 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326624686 | ||
| 035 | |a (NLM)34114515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galluzzo, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of brodalumab for the treatment of chronic plaque psoriasis |b a one-year real-life study in the Lazio region, Italy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2022 | ||
| 500 | |a Date Revised 31.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-il17a | |
| 650 | 4 | |a PASIpsoriasis | |
| 650 | 4 | |a brodalumab | |
| 650 | 4 | |a erythroderma | |
| 650 | 4 | |a plaque psoriasis | |
| 650 | 4 | |a pustular | |
| 650 | 4 | |a real-life | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a brodalumab |2 NLM | |
| 650 | 7 | |a 6ZA31Y954Z |2 NLM | |
| 700 | 1 | |a Caldarola, G |e verfasserin |4 aut | |
| 700 | 1 | |a De Simone, C |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardini, N |e verfasserin |4 aut | |
| 700 | 1 | |a Moretta, G |e verfasserin |4 aut | |
| 700 | 1 | |a Pallotta, S |e verfasserin |4 aut | |
| 700 | 1 | |a Botti, E |e verfasserin |4 aut | |
| 700 | 1 | |a Campione, E |e verfasserin |4 aut | |
| 700 | 1 | |a Pirro, F |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, C |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 21(2021), 9 vom: 24. Sept., Seite 1299-1310 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:9 |g day:24 |g month:09 |g pages:1299-1310 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2021.1941862 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 9 |b 24 |c 09 |h 1299-1310 | ||